Simon Holt's Contact Details

Simon Holt's Company Details

Debiopharm

Lausanne, Vaud, Switzerland • 201 - 500 Employees
Pharmaceuticals

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe. Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. Debiopharm completed the development and licensed out 2 compounds:- Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl®-Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®If you have interesting molecules and seek a competent and committed partner to develop them, please contact us.